Radiopharmaceutical Therapy (RPT) is an emerging modality with significant potential to impact future oncological management across many disease settings.

Theranostics, a treatment paradigm pairing diagnostic molecular imaging with radiopharmaceutical therapy (RPT), is resurgent, mainly driven by the FDA approvals of 177Lu-dotatate for neuroendocrine tumors and 177Lu-PSMA-617 for prostate cancer.

Radiation dosimetry plays a critical role in the development and application of radiotherapeutic pharmaceuticals, ensuring both efficacy and safety in treatment.

Radiopharmaceuticals are an increasingly utilized therapeutic option for the treatment of malignancies.

Despite the rapid advancements, there exists a gap in the integration of radiopharmaceutical therapy within radiation oncology practices.

Radiopharmaceuticals are an increasingly utilized therapeutic option for the treatment of malignancies.

Topics Covered:

Therapy-Specific Considerations I - Therapy-Specific Considerations for Lu-PSMA-617
—Jeff M. Michalski, MD, MBA, FASTRO

Topics Covered:

Miscellaneous and Future Applications of Radiopharmaceutical Therapy – How To Become an Authorized User, Meta-iodobenzylguanidine, Rhenium Skin Cancer Therapy, Radiosynoviorthesis, Alpha Emitters, Other

Topics Covered:

Principles of Patient-Centered Clinical Radiopharmaceutical Therapy: Quality and Safety 
—Hyun Kim, MD

For the presentation description, please see the Program tab.

Topics Covered:

Introduction to Radiopharmaceutical Therapy and Curriculum Overview
—Ana Kiess, MD, PhD

Pages

Subscribe to RSS - Radiopharmaceutical Therapy